Mabwell Biotech

About:

Mabwell Biotech is a Chinese innovative biopharmaceutical company.

Top Investors: Oriental Fortune Capital, Loyal Valley Capital, Huajin Capital, Sincere Capital, Founder H Fund

Description:

Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.

Total Funding Amount:

$279M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Shanghai, Shanghai, China

Founded Date:

2017-01-01

Founders:

Datao Liu

Number of Employees:

501-1000

Last Funding Date:

2020-04-29

IPO Status:

Private

Industries: